MXPA05008561A - Uso de esteroides para tratar personas que sufren de trastornos oculares. - Google Patents

Uso de esteroides para tratar personas que sufren de trastornos oculares.

Info

Publication number
MXPA05008561A
MXPA05008561A MXPA05008561A MXPA05008561A MXPA05008561A MX PA05008561 A MXPA05008561 A MX PA05008561A MX PA05008561 A MXPA05008561 A MX PA05008561A MX PA05008561 A MXPA05008561 A MX PA05008561A MX PA05008561 A MXPA05008561 A MX PA05008561A
Authority
MX
Mexico
Prior art keywords
steroids
ocular disorders
treat ocular
treat
disorders
Prior art date
Application number
MXPA05008561A
Other languages
English (en)
Spanish (es)
Inventor
M Robertson Stella
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MXPA05008561A publication Critical patent/MXPA05008561A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MXPA05008561A 2003-02-20 2004-02-04 Uso de esteroides para tratar personas que sufren de trastornos oculares. MXPA05008561A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44894303P 2003-02-20 2003-02-20
PCT/US2004/003138 WO2004073607A2 (en) 2003-02-20 2004-02-04 Use of steroids to treat ocular disorders

Publications (1)

Publication Number Publication Date
MXPA05008561A true MXPA05008561A (es) 2005-11-04

Family

ID=32908674

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008561A MXPA05008561A (es) 2003-02-20 2004-02-04 Uso de esteroides para tratar personas que sufren de trastornos oculares.

Country Status (16)

Country Link
US (2) US20060154910A1 (xx)
EP (1) EP1670480A4 (xx)
JP (1) JP2006518382A (xx)
KR (1) KR20050102652A (xx)
CN (1) CN1750828A (xx)
AR (1) AR043251A1 (xx)
AU (1) AU2004212895A1 (xx)
BR (1) BRPI0407693A (xx)
CA (1) CA2516782A1 (xx)
MX (1) MXPA05008561A (xx)
PL (1) PL378210A1 (xx)
RU (1) RU2005129276A (xx)
TW (1) TW200511996A (xx)
UY (1) UY28202A1 (xx)
WO (1) WO2004073607A2 (xx)
ZA (1) ZA200505989B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065137A1 (en) * 2003-09-23 2005-03-24 Alcon, Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050245497A1 (en) * 2004-04-08 2005-11-03 Penfold Philip L Treatment of ophthalmic conditions
MX339797B (es) * 2005-10-18 2016-06-10 Allergan Inc Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
US20080076742A1 (en) * 2005-10-31 2008-03-27 Wisconsin Alumni Research Foundation Methods and compositions for treating diseases associated with neovascualrization
ITRM20050547A1 (it) * 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
RU2481842C2 (ru) * 2008-03-11 2013-05-20 Алькон Рисерч, Лтд. Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
TW201105363A (en) 2009-07-14 2011-02-16 Univ Yamagata Eye drop for macular edema treatment
EP3238781B1 (en) * 2010-05-10 2019-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
KR101106074B1 (ko) * 2011-05-27 2012-01-18 김선미 교통 시설물 설치용 부착대 및 지주장치
EP3148525B1 (en) 2014-05-30 2023-10-11 Aarhus Universitet Cafestol for treating diabetes
CA2978600A1 (en) 2015-03-06 2016-09-15 Envisia Therapeutics, Inc. Implant applicators and methods of administering implants
AU2016297187A1 (en) * 2015-07-23 2018-02-15 Aerie Pharmaceuticals, Inc. Intravitreal drug delivery systems for the treatment of ocular conditions
EP3691654A4 (en) * 2017-09-25 2021-11-24 Surface Pharmaceuticals, Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6172054B1 (en) * 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
CN1292721C (zh) * 1999-10-21 2007-01-03 爱尔康公司 药物释放装置
ES2240180T3 (es) * 1999-10-21 2005-10-16 Alcon Inc. Administracion sub-tenon de medicamentos.
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
US20030023228A1 (en) * 2001-07-20 2003-01-30 Parkinson Thomas M. Ocular iontophoretic device and method for using the same

Also Published As

Publication number Publication date
ZA200505989B (en) 2006-12-27
EP1670480A4 (en) 2007-10-10
CN1750828A (zh) 2006-03-22
AR043251A1 (es) 2005-07-20
WO2004073607A3 (en) 2004-11-25
PL378210A1 (pl) 2006-03-20
US20060154910A1 (en) 2006-07-13
US20040171598A1 (en) 2004-09-02
JP2006518382A (ja) 2006-08-10
EP1670480A2 (en) 2006-06-21
RU2005129276A (ru) 2006-01-27
WO2004073607A2 (en) 2004-09-02
CA2516782A1 (en) 2004-09-02
TW200511996A (en) 2005-04-01
AU2004212895A1 (en) 2004-09-02
KR20050102652A (ko) 2005-10-26
UY28202A1 (es) 2004-08-31
BRPI0407693A (pt) 2006-03-01

Similar Documents

Publication Publication Date Title
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
HRP20090195T1 (en) Mitotic kinesin inhibitors
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
DE60329990D1 (de) Mitotische kinesin-hemmer
IL165624A0 (en) Mitotic kinesin inhibitors
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
EP1515949A4 (en) INHIBITORS OF MITOTIC KINESIN
WO2005017190A3 (en) Mitotic kinesin inhibitors
BRPI0506970A (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
MX2007004775A (es) Tratamiento de presbiopia por alteracion del lente.
WO2005018547A3 (en) Mitotic kinesin inhibitors
MX2007004264A (es) Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
AR043252A1 (es) Formulaciones de glucocorticoesteroides para tratar angiogenia ocular patologica
EP2566856A4 (en) COMPOUNDS AND METHODS FOR TREATING CEREBRAL DISORDERS
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal